JP2016514956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514956A5 JP2016514956A5 JP2015561624A JP2015561624A JP2016514956A5 JP 2016514956 A5 JP2016514956 A5 JP 2016514956A5 JP 2015561624 A JP2015561624 A JP 2015561624A JP 2015561624 A JP2015561624 A JP 2015561624A JP 2016514956 A5 JP2016514956 A5 JP 2016514956A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cell
- pharmaceutical composition
- binds
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 claims 9
- 230000003612 virological Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 241000432074 Adeno-associated virus Species 0.000 claims 3
- 102100005826 CD19 Human genes 0.000 claims 3
- 101700087100 CD19 Proteins 0.000 claims 3
- 102100016627 EPHA2 Human genes 0.000 claims 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims 3
- 241000713666 Lentivirus Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000038129 antigens Human genes 0.000 claims 3
- 108091007172 antigens Proteins 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 101700056583 CD27 Proteins 0.000 claims 1
- 102100019459 CD27 Human genes 0.000 claims 1
- 101700033362 CD28 Proteins 0.000 claims 1
- 102100019461 CD28 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 101710044657 FCGR3B Proteins 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100009537 TNFRSF9 Human genes 0.000 claims 1
- 101710040535 TNFRSF9 Proteins 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000174 oncolytic Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Claims (14)
- １種または複数の細胞表面分子に結合する活性化ドメインと、ＥｐｈＡ２および／またはＣＤ１９に結合する抗原認識ドメインとを含む二部分分子をコードするポリヌクレオチドベクターを含む細胞。
- 前記活性化ドメイン、抗原認識ドメイン、または両方のドメインが、一本鎖可変領域断片（ｓｃＦＶ）抗体部分を含む、請求項１に記載の細胞。
- 前記活性化ドメインが、ＣＤ３、ＣＤ１６、ＣＤ２７、ＣＤ２８、ＣＤ４０、ＣＤ１３４、およびＣＤ１３７からなる群から選択される分子を認識するｓｃＦＶである、請求項１に記載の細胞。
- 前記ベクターが、非ウイルスベクターまたはウイルスベクターである、請求項１に記載の細胞。
- 前記ウイルスベクターが、レンチウイルス、アデノウイルス、レトロウイルス、およびアデノ随伴ウイルスベクターからなる群から選択される、請求項４に記載の細胞。
- 前記ベクターが、腫瘍溶解ベクターである、請求項１に記載の細胞。
- １種または複数の請求項１に記載の細胞の治療有効量を含み、がんを有する個体に対して送達するための、医薬組成物。
- 前記がんが、ＥｐｈＡ２陽性またはＣＤ１９陽性である、請求項７に記載の医薬組成物。
- 前記ベクターが、レンチウイルス、アデノウイルス、レトロウイルス、およびアデノ随伴ウイルスベクターからなる群から選択される、請求項７に記載の医薬組成物。
- 前記個体に、追加のがん療法が提供される、請求項７に記載の医薬組成物。
- 前記追加のがん療法が、外科手術、放射線照射、化学療法、ホルモン療法、免疫療法、またはこれらの組合せである、請求項１０に記載の医薬組成物。
- １種または複数の細胞表面分子に結合する活性化ドメインと、ＥｐｈＡ２またはＣＤ１９に結合する抗原認識ドメインとを含む二部分分子をコードするポリヌクレオチドベクター。
- 前記ベクターが、非ウイルスベクターまたはウイルスベクターである、請求項１２に記載のベクター。
- 前記ウイルスベクターが、レンチウイルス、アデノウイルス、レトロウイルス、およびアデノ随伴ウイルスベクターからなる群から選択される、請求項１２に記載のベクター。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772803P | 2013-03-05 | 2013-03-05 | |
| US61/772,803 | 2013-03-05 | ||
| US201361775524P | 2013-03-09 | 2013-03-09 | |
| US61/775,524 | 2013-03-09 | ||
| US201461928383P | 2014-01-16 | 2014-01-16 | |
| US61/928,383 | 2014-01-16 | ||
| US201461941729P | 2014-02-19 | 2014-02-19 | |
| US61/941,729 | 2014-02-19 | ||
| PCT/US2014/020919 WO2014138306A1 (en) | 2013-03-05 | 2014-03-05 | Engager cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018193647A Division JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514956A JP2016514956A (ja) | 2016-05-26 |
| JP2016514956A5 true JP2016514956A5 (ja) | 2017-03-30 |
| JP6420776B2 JP6420776B2 (ja) | 2018-11-07 |
Family
ID=51491924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561624A Expired - Fee Related JP6420776B2 (ja) | 2013-03-05 | 2014-03-05 | 免疫療法のためのエンゲージャー細胞 |
| JP2018193647A Active JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018193647A Active JP6867347B2 (ja) | 2013-03-05 | 2018-10-12 | 免疫療法のためのエンゲージャー細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160015749A1 (ja) |
| EP (2) | EP2964675B1 (ja) |
| JP (2) | JP6420776B2 (ja) |
| AU (1) | AU2014225788B2 (ja) |
| CA (1) | CA2904230A1 (ja) |
| ES (1) | ES2681948T3 (ja) |
| HK (1) | HK1219967A1 (ja) |
| WO (1) | WO2014138306A1 (ja) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4279512A3 (en) | 2010-11-30 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| EP2964241A1 (en) * | 2013-03-05 | 2016-01-13 | Baylor College Of Medicine | Oncolytic virus |
| BR112016022912A2 (pt) | 2014-04-07 | 2017-10-17 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao antígeno de imunoativação |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| CN107106670A (zh) * | 2014-10-31 | 2017-08-29 | 宾夕法尼亚大学董事会 | 用于修饰的t细胞的方法和组合物 |
| EP3218413A4 (en) | 2014-11-12 | 2018-03-28 | Memorial Sloan-Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| US10865245B2 (en) | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| US9963509B2 (en) | 2014-12-23 | 2018-05-08 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| JP6920786B2 (ja) * | 2015-08-26 | 2021-08-18 | ドイチェス クレブスフォルシュンクスツェントルム | 免疫ウイルス療法のためのｒｎａウイルス |
| US11649435B2 (en) * | 2015-08-28 | 2023-05-16 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| RU2770001C2 (ru) * | 2015-10-06 | 2022-04-14 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Терапевтические соединения и способы |
| US20180280435A1 (en) * | 2015-10-09 | 2018-10-04 | Virginia Commonwealth University | T cell delivery of mda-7/il-24 to improve therapeutic eradication of cancer and generate protective antitumor immunity |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| EP3378487B1 (en) | 2015-11-18 | 2022-03-16 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN109641047A (zh) | 2016-05-20 | 2019-04-16 | 哈普恩治疗公司 | 单结构域血清白蛋白结合蛋白质 |
| SG11201810331YA (en) | 2016-05-20 | 2018-12-28 | Harpoon Therapeutics Inc | Single chain variable fragment cd3 binding proteins |
| RU2021127872A (ru) * | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN109689686B (zh) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
| MX2019006045A (es) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| AU2018251206A1 (en) * | 2017-04-14 | 2019-10-31 | The General Hospital Corporation | Chimeric antigen receptor T cells targeting the tumor microenvironment |
| JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス，インク． | メソテリン結合タンパク質 |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| US11525004B2 (en) * | 2017-07-20 | 2022-12-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant CD123-binding antibodies |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
| KR102569133B1 (ko) | 2017-10-13 | 2023-08-21 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| KR20230117641A (ko) * | 2018-05-08 | 2023-08-08 | 주식회사 뉴라클사이언스 | 항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113286817A (zh) | 2018-09-25 | 2021-08-20 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3870297B1 (en) * | 2018-10-25 | 2023-08-30 | Baylor College of Medicine | Oncolytic virotherapy and immunotherapy |
| AU2019397152A1 (en) * | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20210122268A (ko) * | 2019-01-30 | 2021-10-08 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 암 항원을 표적화하는 dna-인코딩된 이중특이적 t-세포 인게이저 및 암 치료에서 사용 방법 |
| JP2022526856A (ja) * | 2019-04-12 | 2022-05-26 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
| CN111001016B (zh) * | 2019-12-20 | 2022-06-17 | 中国人民解放军陆军军医大学 | 一种vha抑制dr5在缺氧下精子生成减少的检测方法 |
| EP3865513A1 (en) * | 2020-02-17 | 2021-08-18 | Fundación Para La Investigación Biomédica Del Hospital 12 De Octubre | Anti-cd19/anti-cd3 bispecific antibody, t cells secreting the same, method of preparation and use thereof |
| CN115768463A (zh) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | Flt3结合蛋白及使用方法 |
| CN113481165B (zh) * | 2020-07-16 | 2022-06-03 | 山东博安生物技术股份有限公司 | 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2023102119A1 (en) * | 2021-12-01 | 2023-06-08 | The Brigham And Women's Hospital, Inc. | Multispecific t cell engager polypeptides in combination with t cells for cancer therapy |
| KR102532260B1 (ko) * | 2022-07-07 | 2023-05-16 | 주식회사 유틸렉스 | 돌연변이 EGFR 및 EphA2를 동시 타겟하는 키메라 항원 수용체 |
| WO2024010119A1 (ko) * | 2022-07-07 | 2024-01-11 | 주식회사 유틸렉스 | 돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체 |
| WO2024040261A1 (en) * | 2022-08-19 | 2024-02-22 | The Children's Hospital Of Philadelphia | Gd2 bi-specific invariant natural killer t cell engagers and methods of use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| TR200003087T2 (tr) | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
| US7820166B2 (en) * | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| BRPI0415457A (pt) * | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
| AU2006327175A1 (en) * | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
| US20080004413A1 (en) | 2006-06-30 | 2008-01-03 | Derek Schorzman | Carboxylic M2Dx-like siloxanyl monomers |
| WO2009091826A2 (en) * | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| SG10201510092QA (en) * | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| ES2786263T3 (es) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
-
2014
- 2014-03-05 US US14/773,327 patent/US20160015749A1/en not_active Abandoned
- 2014-03-05 ES ES14714473.7T patent/ES2681948T3/es active Active
- 2014-03-05 EP EP14714473.7A patent/EP2964675B1/en not_active Revoked
- 2014-03-05 WO PCT/US2014/020919 patent/WO2014138306A1/en active Application Filing
- 2014-03-05 AU AU2014225788A patent/AU2014225788B2/en active Active
- 2014-03-05 JP JP2015561624A patent/JP6420776B2/ja not_active Expired - Fee Related
- 2014-03-05 CA CA2904230A patent/CA2904230A1/en not_active Abandoned
- 2014-03-05 EP EP18171595.4A patent/EP3447072A3/en not_active Withdrawn
-
2016
- 2016-07-11 HK HK16108096.8A patent/HK1219967A1/zh unknown
-
2018
- 2018-08-22 US US16/109,615 patent/US20190117692A1/en not_active Abandoned
- 2018-10-12 JP JP2018193647A patent/JP6867347B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514956A5 (ja) | ||
| JP2016512199A5 (ja) | ||
| EA201791971A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2020503891A5 (ja) | ||
| JP2017176174A5 (ja) | ||
| MX2019003462A (es) | Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer. | |
| JP2015096070A5 (ja) | ||
| JP2016104790A5 (ja) | ||
| EA201891021A1 (ru) | Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| WO2015112805A8 (en) | Human antibodies to pd-l1 | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| JP2017531427A5 (ja) | ||
| JP2016538855A5 (ja) | ||
| MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| WO2016054598A3 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| JP2015535691A5 (ja) | ||
| MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
| JP2016116527A5 (ja) | ||
| JP2018509163A5 (ja) | ||
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| JP2017518260A5 (ja) | ||
| JP2017501695A5 (ja) |